secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2026-08-13T20:11:12+00:00
Accession:  0001193125-26-349197
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics Q2 2026 net loss $8.4M; RT-114 oral bioavailability >150% vs subcutaneous
--------------------------------------------------------------------------------

- RT-114 Phase 1a: oral bioavailability >150% vs matched subcutaneous PG-102; no serious adverse events.
- First participants dosed in Phase 1a expansion cohort; Phase 1b in obesity expected by end 2026.
- Completed $20M registered direct offering; cash $53.4M as of June 30, 2026, sufficient through 2027.
- New PegBio collaboration to explore oral delivery of obesity/metabolic molecules via RaniPill.
- Appointed Nicholas Maestas as CFO and Michelle Gilson to Board; net loss $8.4M vs $11.2M YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000119312526349197/0001193125-26-349197-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000119312526349197/rani-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-349197

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer